Keywords
How to Cite
Abstract
Richter syndrome (SR) is defined as the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL). SR that develops under treatment with ibrutinib exhibits special characteristics, frequently presenting with bulky lymph node or extranodal disease, similar to highly aggressive DLBCL, alteration in TP53 gene, complex karyotype and greatly shortened survival. This article reports a patient with a diagnosis of CLL with loss of an allele of the TP53 gene who undergoes a transformation from Richter to LDCGB of torpid evolution under treatment with ibrutinib.
References
2. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761-2772
3. Puła P, Salomon-Perzyński A, Prochorec-Sobieszek J, Jamroziak K. Immunochemotherapy for Richter syndrome: current insights. Immunotargets Ther. 2019; 8: 1–14.
4. Ding W. Richter transformation in the era of novel agents. Hematology Am Soc Hematol Educ Program. 2018 Nov 30; 2018(1): 256–263.
5. Allan J, Furman R. Current trends in the management of Richter´s síndrome. Int J Hematol Oncol . 2018 dic; 7 (4): IJH09.
6. Innocenti I, Rossi D, Trapè G. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. 2018 Hematological Oncology.1–4.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar